SAN FRANCISCO - Better Therapeutics Inc. (NASDAQ: BTTX), a developer of prescription digital therapeutics for cardiometabolic diseases, has announced health economic data indicating that its AspyreRx treatment for type 2 diabetes, when combined with standard care, is more cost-effective and clinically superior than standard care alone. The study, published in the peer-reviewed medical journal Advances in Therapy, suggests that AspyreRx could offer patients a better way to manage their diabetes and potentially reduce long-term complications.
The study, based on a healthcare payer perspective, found that the addition of AspyreRx to standard care resulted in both quality-adjusted life years (QALYs) gains and cost savings of $7,343 per patient over a lifetime horizon. The cost-effectiveness of AspyreRx was evident at various willingness-to-pay thresholds, with incremental net monetary benefits ranging from $12,393 to $22,493. The savings were mainly due to reduced drug costs and fewer adverse events.
This announcement comes against the backdrop of rising diabetes prevalence and costs in the United States. The American Diabetes Association reported an estimated national cost of diabetes at $412.9 billion in 2022, with a significant portion due to direct healthcare expenditures.
AspyreRx is the first FDA-authorized prescription-only digital therapeutic for adults with type 2 diabetes. The treatment employs cognitive behavioral therapy techniques to address psychological and behavioral factors contributing to the disease. It is designed for use on a patient's smartphone and is prescribed in 90-day increments.
The study's findings add to the evidence supporting the efficacy and economic viability of digital therapeutics. Niall Davison, Senior Scientific Lead at Maple Health Group, emphasized the importance of integrating such innovative treatments into clinical practice to benefit patients and the healthcare system financially.
Frank Karbe, President and CEO of Better Therapeutics, highlighted the study's alignment with the company's vision to improve health outcomes and reduce healthcare costs. The company aims to address the underlying factors of cardiometabolic diseases through its proprietary platform and FDA-regulated software-based solutions.
The information in this article is based on a press release statement from Better Therapeutics Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.